However, the FDA approval of anti-CTLA4 or anti-PD1 checkpoint strategy typically suggests that there is an urgent need to combine them with other therapeutic approaches such as cancer vaccines, different cytokines, TAM and TLR agonists to boost the efficacy of endogenous adaptive immune response against particular tumor sites without any complications or side effects. This evidence concerns the gene CTLA4 and cancer.